 |
|
|
|
 |
|
|
 Contact |  Print version |  PDF version |  Recommend company
|
| Vela pharm. Entwicklung u. Laboranalytik GmbH |
Brunnerstr. 69/3, Novartis-Campus
1230 Wien
Austria
|
|
Portrait
Vela Laboratories (Vela pharmazeutische Entwicklung und Laboranalytik GmbH) provides a broad portfolio of analytical methods for the preclinical and clinical development including studies in support of regulatory submissions and product release for biopharmaceuticals.
Additionally, Vela Laboratories develops innovative immunotherapeutics for the treatment of cancer, including therapeutic antibodies and multi-epitope vaccines. Vela Laboratories’ lead product, a humanized monoclonal antibody against a common tumor antigen, is in clinical development. In addition, Vela Laboratories also has development programs underway that aim at improving the efficacy and tolerability of therapeutic antibodies through targeted changes to the sugar structure of the antibody molecules.
The Company, headquartered in Vienna, Austria, was founded in November 2006. Vela Laboratories is funded by private investors, by grants from Austrian government agencies (AWS and ZIT/LISA) and through revenues generated by its analytical services business.
Industrial Sectors
Additional information
Vela pharm. Entwicklung u. Laboranalytik GmbH
Wien, Austria
News
|
|
|
|
|
|
Top
